With the advancement of next generation sequencing in past several years, a rising number of non-coding RNAs have been found as new actors to regulate gene expression. Non-coding RNAs not only play important roles in carcinogenesis, but also affect the clinical treatment strategies. They have been proved to be deeply correlated with chemoresistance in several cancers. Ovarian cancer is the leading cause of death in gynecological malignancy, with low 5-year survival rate. Most patients are identified when they have late-stage disease. This review mainly makes a compilation of the most relevant research literature in this field with the purpose of shedding light on the relation between ncRNAs and chemoresistance in ovarian cancer.

Three monoruthenium complexes 1(PF6)23(PF6)2 bearing a N(CH3)-bridged ligand have been synthesized and characterized. These complexes have a general formula of [Ru(bpy)2(L)](PF6)2, where L is a 2,5-di(N-methyl-N-(pyrid-2-yl)amino)pyrazine (dapz) derivative with various substituents and bpy is 2,2′-bipyridine. The photophyscial and electrochemical properties of these compounds have been examined. The solid-state structure of complex 3(PF6)2 is studied by single crystal X-ray analysis. These complexes show two well-separated emission bands centered at 451 and 646 nm (max = 195 nm) for 1(PF6)2, 465 and 627 nm (max = 162 nm) for 2(PF6)2, and 455 and 608 nm (max = 153 nm) for 3(PF6)2 in dilute acetonitrile solution, respectively. The emission maxima of the higher-energy emission bands of these complexes are similar, while the lower-energy emission bands are dependent on the electronic nature of substituents. These complexes display two consecutive redox couples owing to the stepwise oxidation of the N(CH3)-bridged ligand and ruthenium component. In addition, density functional theory (DFT) and time-dependent density functional theory (TD-DFT) calculations are carried out to elucidate these experimental findings.